Comphya has closed an oversubscribed Series A round that brings its total equity raised to CHF 7.5 million (approximately $8.4 million).
The company earmarked the funds to advance clinical programs for CaverSTIM, an implantable neurostimulation system intended for men with erectile dysfunction that does not respond to medication.
Related: Piur Imaging closes $6.5m funding round for AI tomographic 3D ultrasound
Proceeds will launch and run a U.S. pilot study approved under an FDA investigational device exemption in January. Johns Hopkins University is the first activated site. The financing will also lay the regulatory and operational groundwork for a pivotal U.S. trial planned for 2026 and expand an ongoing Australian study that has shown positive safety and efficacy signals.
“We are thrilled to have the continued confidence of our investors, which enables us to accelerate our mission to bring a transformative solution to men living with erectile dysfunction following treatment for prostate cancer,” said Pim van Wesel, CEO of Comphya. “With our U.S. pilot study underway and preparations beginning for a pivotal clinical trial, we’re entering an important new chapter in our development.”
Early Australian data presented at the 2025 American Urological Association meeting in Las Vegas indicated that most patients maintained good erectile function after robotic-assisted prostatectomy without additional therapy, with no infections or adverse events reported.
CaverSTIM is designed to restore natural erections by stimulating the cavernous nerves. The system pairs a rechargeable implantable pulse generator with two electrode arrays placed in the pelvic cavity and is controlled by a clinician and a patient’s remote.
The Series A close follows van Wesel’s appointment as CEO in May. Comphya, founded in 2017 as an EPFL spinoff, is planning a Series B round to finance its pivotal U.S. trial.
